Jun 2026 (Q2 FY26) — Aug 6, 2026
TriSalus Life Sciences Q2 FY26 — Strong Revenue Growth and Expanded Reimbursement
Read the full callTriSalus Life Sciences (TLSI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
TriSalus Life Sciences earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 11.4 | +1.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -86.0 | −20.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -9.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.53 −2.75% · −$0.1
Performance −29.7% 1Y
1Y: $5.02 on 17 Oct 2025 → $3.53. High $7.5 (11 Dec 2025), low $2.52 (14 May 2026).
- Previous close
- $3.63
- 52-week range
- $2.52 – $7.5
- One year
- −33.14%
Overview
- Symbol
- TLSI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
TriSalus Life Sciences earnings calls (TLSI)
Financials
What the filings say
Net profit, year on year: −11% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 8 | 9 | 11 | 12 | 13 | 9 | 11 |
| Operating profit | -9 | -8 | -7 | -7 | -9 | -3 | -8 | -10 |
| Operating margin | −118.9% | −91.8% | −80.0% | −65.4% | −77.9% | −24.8% | −94.5% | −86.0% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -2 | -10 | -10 | -8 | -11 | -10 | 2 | -9 |
| Tax rate | 0.1% | 0.0% | −0.1% | 0.0% | −0.1% | 0.0% | 0.3% | −0.0% |
| Net profit | -2 | -10 | -10 | -8 | -11 | -10 | 2 | -9 |
| EPS ($ per share) | -0.12 | — | -0.39 | -0.27 | -0.96 | — | 0.03 | -0.16 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 |
| Reserves | -17 | -186 | -250 | -280 | -331 |
| Total liabilities | 17 | 34 | 52 | 50 | 69 |
| Fixed assets | — | 2 | 2 | 2 | 2 |
| Total assets | 251 | 22 | 25 | 24 | 35 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -2 | -32 | -51 | -41 | -18 |
| Cash from investing | 0 | -2 | -2 | -0 | -1 |
| Cash from financing | 1 | 13 | 55 | 38 | 31 |
| Net cash flow | -1 | -21 | 2 | -3 | 12 |
| Capital expenditure | — | -1 | -1 | -0 | -1 |
| Free cash flow | — | -33 | -51 | -41 | -19 |
Insider filings
53 filings between Nov 24, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$3.61M
12 purchases by 6 insiders
Sales
$139.9K
18 sales by 5 insiders
Compensation
not trading decisions- 21
- Award — granted as compensation
- 2
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Stansky Michael P | $3.01M | — | May 15, 2026 |
| Szela Mary T | $227.8K | $79.4K | May 15, 2026 |
| Wahlstrom Mats | $151.8K | — | May 15, 2026 |
| Valle William | $125.0K | — | Feb 23, 2026 |
| Gordon Gary B. | $64.6K | — | May 15, 2026 |
| Patience David | $32.2K | — | May 15, 2026 |
| Marshak Richard | — | $17.1K | Oct 5, 2026 |
| Stevens Jennifer | — | $15.9K | Oct 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Marshak Richard Chief Commercial Officer | Sale | 325 | $1.4K |
| Oct 5, 2026 | Cox Bryan F. Chief of Research | Sale | 296 | $1.3K |
| Oct 5, 2026 | Szela Mary T CEO and President | Tax withheld | 2,693 | $11.8K |
| Oct 5, 2026 | Stevens Jennifer Chief Regulatory Officer | Sale | 316 | $1.4K |
| Jul 1, 2026 | Patience David Chief Financial Officer | Tax withheld | 14,650 | $65.3K |
| Jun 30, 2026 | Szela Mary T CEO and President | Award | 3,990 | $15.4K |
| Jun 30, 2026 | Marshak Richard Chief Commercial Officer | Award | 561 | $2.2K |
| Jun 29, 2026 | Marshall Richard Henry Chief Medical Officer | Award | 60,000 | $0 |
| May 15, 2026 | Marshak Richard Chief Commercial Officer | Sale | 543 | $1.4K |
| May 15, 2026 | Stansky Michael P Director | Purchase | 410,000 | $1.02M |
| May 15, 2026 | Patience David Chief Financial Officer | Purchase | 7,100 | $17.3K |
| May 15, 2026 | Gordon Gary B. Director | Purchase | 10,000 | $24.6K |
| May 15, 2026 | Wahlstrom Mats Director | Purchase | 60,000 | $151.8K |
| May 15, 2026 | Stansky Michael P Director | Purchase | 200,000 | $500.0K |
| May 15, 2026 | Szela Mary T CEO and President | Purchase | 39,682 | $102.8K |
| May 14, 2026 | Valle William Director | Award | 24,553 | $0 |
| May 14, 2026 | Valle William Director | Award | 28,201 | $0 |
| May 14, 2026 | Stansky Michael P Director | Award | 20,089 | $0 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 37,602 | $0 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 34,226 | $0 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 28,201 | $0 |
| May 14, 2026 | HICKS KERRY R Director | Award | 28,201 | $0 |
| May 14, 2026 | Gordon Gary B. Director | Award | 24,553 | $0 |
| May 14, 2026 | Gordon Gary B. Director | Award | 28,201 | $0 |
| May 14, 2026 | Stansky Michael P Director | Award | 23,501 | $0 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 23,065 | $0 |
| Mar 17, 2026 | Szela Mary T CEO and President | Sale | 15,944 | $61.4K |
| Mar 16, 2026 | Stevens Jennifer Chief Regulatory Officer | Sale | 774 | $3.2K |
| Mar 16, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 273 | $1.1K |
| Mar 16, 2026 | Cox Bryan F. Chief of Research | Sale | 579 | $2.4K |
| Mar 16, 2026 | Marshak Richard Chief Commercial Officer | Sale | 419 | $1.7K |
| Mar 12, 2026 | Marshak Richard Chief Commercial Officer | Sale | 1,589 | $6.5K |
| Mar 12, 2026 | Stevens Jennifer Chief Regulatory Officer | Sale | 1,552 | $6.3K |
| Mar 12, 2026 | Cox Bryan F. Chief of Research | Sale | 1,467 | $6.0K |
| Mar 12, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,772 | $7.2K |
| Mar 11, 2026 | Marshak Richard Chief Commercial Officer | Sale | 1,449 | $6.0K |
| Mar 11, 2026 | Stevens Jennifer Chief Regulatory Officer | Sale | 1,204 | $5.0K |
| Mar 11, 2026 | Szela Mary T CEO and President | Sale | 4,358 | $18.0K |
| Mar 11, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,162 | $4.8K |
| Mar 11, 2026 | Cox Bryan F. Chief of Research | Sale | 1,138 | $4.7K |
| Feb 23, 2026 | Stansky Michael P Director | Purchase | 243,900 | $1000.0K |
| Feb 23, 2026 | Patience David Chief Financial Officer | Purchase | 3,657 | $15.0K |
| Feb 23, 2026 | Gordon Gary B. Director | Purchase | 9,756 | $40.0K |
| Feb 23, 2026 | Valle William Director | Purchase | 30,487 | $125.0K |
| Feb 23, 2026 | Szela Mary T CEO and President | Purchase | 30,487 | $125.0K |
| Feb 23, 2026 | Stansky Michael P Director | Purchase | 117,198 | $480.5K |
| Nov 24, 2025 | Stevens Jennifer Chief Regulatory Officer | Award | 50,000 | $0 |
| Nov 24, 2025 | Cox Bryan F. Chief of Research | Award | 40,000 | $0 |
| Nov 24, 2025 | Patience David Chief Financial Officer | Award | 65,000 | $0 |
| Nov 24, 2025 | Devlin Jodi Chief of Clinical Operations | Award | 50,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TriSalus Life Sciences, Inc.
Free account. Everything above stays public.
Write why you follow TriSalus Life Sciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading